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benefit from reinfusion has been difficult.6-9 Some
authors have questioned the safety of mediastinal blood
reinfusion regarding a possible association with coagu-
lopathy,10 but this technique has been clinically proven
safe, although not necessarily useful.11-13
Recently, de Varennes and associates3 reported their
experience with reinfusion of mediastinal shed blood
after first-time isolated coronary artery bypass opera-
tions in 337 patients. They showed a significant de-
crease in total exposure to homologous transfusions:
48% of patients in the autotransfusion group received
homologous transfusions compared with 82% in the
control group. Because this study compared 2 nonran-
domized groups of patients (a historical control study),
the methodologic design can be criticized.
Still debated, the role of autotransfusion of mediasti-
nal shed blood remains of concern because approxi-
mately 60% of patients undergoing heart operations in
our institution receive homologous blood transfusions
in the postoperative period. In addition to the infectious
and immune reaction risks associated with blood trans-
fusions, the newly introduced modality of distribution
R einfusion of blood collected from the mediastinumof patients after cardiac operations was first report-
ed by Schaff and colleagues1 in 1978. Since then, many
studies have suggested that reinfusion may help
decrease the number of homologous transfusions need-
ed in the postoperative period.2-5 On the other hand,
conflicting results have also been published, and identi-
fication of subgroups of patients who might especially
Background: Several authors studying autotransfusion of shed mediastinal
blood in patients undergoing heart operations have published conflicting
results regarding reduction of the need for homologous blood transfusion.
The effect on coagulation parameters is also unclear.
Methods: In a prospective randomized study, 198 patients who underwent
coronary artery bypass grafting or a valvular operation were divided into 2
groups: a group with autotransfusion of shed mediastinal blood after an oper-
ation and a control group. Continuous reinfusion of mediastinal blood was
done until no drainage was present or for a period of 12 hours after the oper-
ation. The amount of blood lost and autotransfused, the number of homolo-
gous blood products transfused, and the coagulation parameters were moni-
tored.
Results: The number of patients requiring homologous blood transfusion was
significantly different between the 2 groups (54/98 [55%] in autotransfused
patients vs 73/100 [73%] in the control group, P = .01). The number of re-
explorations for excessive bleeding was similar in the 2 groups (7/98 [7.1%]
vs 8/100 [8%]), but the amount of blood collected postoperatively was high-
er in the autotransfused patients compared with control patients (1200 ± 201
mL vs 758 ± 152 mL, P = .0007). Coagulation parameters analyzed and
complication rates were similar in the 2 groups after the operations.
Conclusion: Autotransfusion of shed mediastinal blood reduces the need for
homologous blood transfusion in patients undergoing various cardiac opera-
tions. The cause of increased shed blood in patients undergoing autotransfu-
sion remains unclear. (J Thorac Cardiovasc Surg 2000;120:499-504)
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of blood products in the Canadian health system will
engender extra costs to hospitals having a high con-
sumption of these products. Hence any strategy
designed to decrease the number of homologous trans-
fusions is of great interest.
We therefore undertook a prospective randomized
clinical trial to compare the current approach of medi-
astinal drainage without reinfusion to a system specifi-
cally designed for reinfusion. The primary aim of our
study was to determine the effect of reinfusion on the
percentage of patients requiring any type of homolo-
gous blood product transfusions and on the number of
blood product units transfused per patient after a heart
operation. Secondarily, we wanted to measure the
effects of reinfusion on blood levels of hemoglobin,
platelets, and coagulation parameters. Finally, we
looked to define which category of patients would most
benefit from reinfusion of mediastinal shed blood after
cardiac operations.
Methods
Study population. From September 1998 to January 1999,
patients admitted to our institution for coronary artery bypass
grafting operations, valvular replacement, or both procedures
under cardiopulmonary bypass (CPB) were offered the option
to participate in the study. Written informed consent was
obtained from all recruited patients after explanation of the
potential risks and benefits of the study approaches. Patients
with a prior history of cardiac intervention were also eligible.
Exclusion criteria consisted of preoperative known coagu-
lopathy or patients unable to give an informed consent.
Technical procedure. In the control group, postopera-
tive mediastinal drainage was achieved by the currently
used system that consists of 24F double-lumen soft sump
drains under high-pressure wall suction, from which col-
lected blood is discarded. In the treatment group, mediasti-
nal drainage was achieved with a commercially available
autotransfusion system (Atrium Medical Corporation,
Hudson, NH). This reinfusion system consists of 28F tho-
racic tubes connected to a 3-chamber system: a collection
chamber, an underwater seal chamber, and a 20-cm H2O
suction control chamber. The 500-mL capacity sterile col-
lection chamber contains 20 mL of adenine-supplemented
citrate dextrose. All collected blood is filtered through an
80-µm filter and autotransfused to the patient hourly until
no drainage was present or for a maximum of 12 hours. The
reinfusion was started 1 hour after the arrival of the patient
in the intensive care unit.
Operative procedure. Perioperative management was
standard. During the operation, heparin was administered as
a 3-mg/kg bolus with possible additional doses to maintain
the activated clotting time above 400 seconds throughout the
CPB time. Anticoagulation was reversed with a 3-mg/kg dose
of protamine sulfate. The use of an antifibrinolytic agent
(aprotinin, aminocaproic acid) was allowed during CPB but
not after weaning from CPB. Before completion of the oper-
ation, the perfusionist would tell the surgeon in which group
the patient had been randomized, and the drainage system
was set up accordingly. Indications for surgical re-explo-
ration for bleeding after the cardiac operations were left to the
surgeon’s discretion.
Intraoperative transfusion. Intraoperative homologous
blood products were administered according to the following
criteria during the study period. During CPB, red blood cells
were transfused for hemoglobin concentration below 60 g/L,
whereas in the postoperative period the threshold for homol-
ogous red blood cell transfusion was 80 g/L. Clotting factors
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Table I.  Characteristics of the 2 patient groups
Characteristics Reinfusion group Control group P value
No. of patients 98 100
Age (y) 62 ± 2 66 ± 2 .009
Sex (M/F) 75/23 70/30 .3
Weight (kg) 79 ± 3 73 ± 3 .008
Body surface area 1.87 ± 0.04 1.79 ± 0.04 .006
Hemoglobin (g/L) 121 ± 3 114 ± 3 .002
Red cell mass* (g · L–1 · m–2) 227 ± 8 206 ± 9 .0007
Platelets (×109/L) 169 ± 9 170 ± 10 .8
Preoperative aspirin (within 7 days) 12% 16% .5
Preoperative intravenous heparin 36% 33% .7
*Red cell mass = Body surface area × Hemoglobin.
Table II. Type of surgical procedures
Reinfusion Control
group group
Procedures (n = 98) (n = 100) P value*
CABG only (%) 74 (76) 76 (76) 1
Valve only (%) 14 (14) 18 (18) .6
CABG and valve (%) 10 (10) 6 (6) .3
Redo (%) 6 (6) 9 (9) .6
were administered for persistent bleeding after correction of
the activated clotting time. Four units of fresh frozen plasma
were given for persistent moderate (100-300 mL/h) or severe
(300 mL/h for 2 hours) bleeding with an international nor-
malized ratio higher than 1.8. For bleeding patients with
platelet counts lower than 80 × 109/L, 8 units of platelets
were transfused, and 8 units of cryoprecipitate were adminis-
tered for fibrinogen levels lower than 1.0 g/L.
Statistical analysis. The study was designed to demon-
strate a decrease from 80% to 50% in the number of patients
exposed to homologous blood products on the basis of the
experience of de Varennes and colleagues.3 It was estimated
that 200 patients had to be randomized into 2 groups. Patients
were randomized in the control group or the reinfusion group
by use of a table of random digits by blocks of 4.
Blood tests and different measurements of standardized
clinical data were done after a strict protocol identical in both
groups. All data were prospectively collected from the chart
of every enrolled patient by 3 research assistants. For the pur-
pose of the study, the term transfusion refers to any adminis-
tration of homologous blood products, including homologous
packed red blood cell units, platelets, fresh frozen plasma,
and cryoprecipitate units.
Data are expressed as means ± 1.96 SEM unless otherwise
specified. Statistical comparisons were done with the
unpaired Student t test for continuous variables and the
Mantel-Haenszel test for rates of exposure. Univariate and
multiple logistic regression analysis was performed to identi-
fy the relationship between the need of homologous blood
transfusion after the operation and several clinical variables
among autotransfused and control patients. Data analyses
were performed by means of Number Cruncher Statistical
System 6.0.21 software (NCSS Statistical Software,
Kaysville, Utah), released March 1996, and SAS 6.12 statis-
tical software (SAS Institute, Inc, Cary, NC).
Results
Of the 198 participants, 196 completed the study in
accordance with the protocol. Two patients randomized
to the reinfusion system were not subjected to the prop-
er study protocol: in 1 case the surgeon requested to use
the usual drainage system, and in the other case the
postoperative protocol was not observed. The data from
those 2 patients are included in the reinfusion group to
perform an intent-to-treat analysis.
Reinfusion and control groups were similar for most
of the clinical and demographic parameters but differed
in their age, weight, and preoperative hemoglobin lev-
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Table III.  Intraoperative characteristics
Reinfusion group Control group
Characteristics (n = 98) (n = 100) P value
Duration of CPB (min) 79 ± 6 76 ± 5 .4
Aortic crossclamp time (min) 51 ± 5 46 ± 4 .2
Antifibrinolytic administration (%) 67 (68) 72 (72) .6
Intraoperative blood loss (mL) 494 ± 82 476 ± 51 .7
Table V.  Coagulation profile
Immediately postoperative Postoperative day 1
Reinfusion group Control group P value Reinfusion group Control group P value
Platelets (× 109/L) 107.3 ± 6.7 102.9 ± 6.8 .4 121.3 ± 6.6 123.2 ± 7.1 .7
Prothrombin time (s) 11.7 ± 0.5 12.0 ± 0.4 .4 9.5 ± 0.2 9.7 ± 0.2 .3
Partial thromboplastin time (s) 36.1 ± 2.7 40.9 ± 3.6 .04 32.0 ± 1.9 37.0 ± 2.7 .003
Table IV. Exposure to homologous blood products
Blood products Reinfusion group (n = 98) Control group (n = 100) P value
Packed red blood cells 1.8 ± 0.7 2.2 ± 0.5 .5
Platelets 3.2 ± 1.2 2.7 ± 0.9 .6
Fresh frozen plasma 1.3 ± 0.7 0.9 ± 0.5 .4
Cryoprecipitate 0.4 ± 0.3 0.4 ± 0.3 .9
Total 6.7 ± 2.7 6.4 ± 1.8 .9
Patients transfused (%) 54 (55) 73 (73) .01
Data are expressed as mean number of units transfused per patient ± 1.96 SD where indicated.
els. Patients in the reinfusion group were younger,
heavier, and had a higher baseline average hemoglobin
level than control patients (Table I). There was no dif-
ference in terms of preoperative platelet counts and
coagulation parameters, although one third of patients
in both groups were administered intravenous heparin
up until the time of the operation for unstable angina
present before the operation. The number of patients
who underwent coronary artery bypass grafting
(CABG), valve procedures, combined operations, and
redo operations was similar in the 2 groups (Table II).
First-time procedures accounted for 94% and 91% of
all operations in the reinfusion and control groups,
respectively. Sixty-seven (69%) patients in the reinfu-
sion group and 72 (72%) in the control group received
intraoperative antifibrinolytic agents (aprotinin,
aminocaproic acid; P = .6). The mean crossclamp time
and CPB time were similar in the 2 groups (Table III).
Although intraoperative blood losses were similar in
the 2 groups, the postoperative amount of blood drained
in the reinfusion group was significantly higher, averag-
ing 1200 ± 201mL compared with 758 ± 152 mL in the
control group (P =.0007, Fig 1). Thus, the total blood
loss (intraoperative and postoperative) was higher in the
reinfusion group, averaging 1684 ± 228 mL compared
with 1233 ± 171 mL in the control group (P = .002). The
mean volume of autotransfused shed blood was 722 ±
105 mL (range, 0-2660 mL) in the reinfusion group. The
mean number of homologous blood products transfused
per patient was similar in the 2 groups, but only 55% of
patients reinfused received homologous blood products
compared with 73% in the control group, a significant
difference between the 2 groups (P =.01, Table IV). The
average hemoglobin level was significantly lower in the
control group throughout the entire study, as was the red
cell mass (hemoglobin × body surface area). There was
no effect of reinfusion of autologous blood on measured
coagulation parameters, as shown in Table V.
Univariate analyses performed to define a target
group of patients who would most benefit from reinfu-
sion showed that older age, male sex, and an increased
amount of drainage through chest tubes were associat-
ed with an increased need of transfusions. On the other
hand, higher preoperative red cell mass, use of an
antifibrinolytic agent, and use of the reinfusion system
were associated with a lower number of transfusions
(Table VI). On multivariate analysis, male sex and the
amount of drainage through chest tubes are still related
to an increased risk of transfusion. Higher preoperative
red cell mass and reinfusion of mediastinal blood col-
lected with a closed system at –20 cm H2O are related
to a decreased risk of any type of homologous blood
transfusion (Table VII).
The overall reoperation rate for bleeding was 7% in
the reinfusion group and 8% in the control group (not
significant). Cerebrovascular accident or transient
ischemic attack occurred in 1 reinfused patient and 2
control subjects. Atrial arrhythmia occurred in 29
patients (16 reinfused patients and 13 control subjects,
P = not significant), and myocardial infarction
occurred in 7 patients (5 reinfused patients and 2 con-
trol subjects, P = not significant). There were 2 in-hos-
pital deaths (mortality rate of 1%) from perioperative
myocardial infarction, both in the control group.
Discussion
The present prospective randomized trial demon-
strates an 18% decrease (from 73%-55%) in the num-
ber of patients exposed to homologous blood products
after CABG, valvular procedures, or both, with the use
of a reinfusion system allowing autotransfusion of the
shed mediastinal blood. However, there was no differ-
ence in the average number of homologous blood prod-
ucts per patient in the 2 groups. The amount of postop-
erative blood loss after the operation was greater in the
reinfused group than in the control group, a difference
that remains unexplained.
The present study concurs with those reported by de
Varennes and colleagues,3 who showed a decrease in
transfusion rates from 82% to 48% in their nonran-
domized study. The unusually high transfusion rate for
the control group of de Varennes and colleagues and in
our control group remains within the range reported by
Goodnough and colleagues14 of 68% for homologous
red blood cell transfusion from 18 US institutions.
However, other studies have shown that it is possible to
perform cardiac operations without homologous red
blood cell transfusion15 or at least with lower rates of
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Fig 1. Blood loss during and after the operation was higher in
the reinfusion group than in the control group (P = .002).
Intra-op, Intraoperative; post-op, postoperative; total, total
blood losses.
homologous red blood cell transfusion, ranging from
10% to 25% of patients in the perioperative period.16
The mean number of homologous blood products
required per patient was similar in the 2 groups.
Goodnough and colleagues14 reported that their
patients undergoing CABG were administered an aver-
age of 2.9 ± 0.1 red blood cell units, 33% of patients
were administered plasma, and 22% of patients
received platelet transfusion at a higher volume and
higher rates than those of the present study. Body and
colleagues17 showed that 41% of patients undergoing
elective primary CABG in 12 US academic medical
centers were administered red blood cell transfusion,
with a mean transfusion volume of 2.4 ± 1.7 units.
Moreover, platelets, fresh frozen plasma, and cryopre-
cipitate units were also administered.
Contrary to Body and colleagues,17 who not only
concluded that there was no benefit to transfusion of
shed mediastinal blood after elective CABG but who
also reported a higher rate of surgical wound infection
among reinfused patients, no wound infection was
observed in the present study nor were any other sig-
nificant side effects observed. Only one early postoper-
ative sternal wound dehiscence occurred in each group.
Although the amount of mediastinal blood loss was
higher in the reinfused group of patients, all coagula-
tion parameters measured in the present study
remained in the normal ranges. Several authors have
suggested that transfusion of mediastinal shed blood
may cause a significant coagulopathy.18 We can
hypothesize that some proinflammatory products pre-
sent in mediastinal shed blood, such as interleukin 6,
may contribute to more important wound oozing and
surgical bleeding in autotransfused patients.19
Studies have also demonstrated that creatine kinase-
MB (CK-MB) blood levels increase when mediastinal
shed blood is reinfused and that measurement of car-
diac troponin is more specific and reliable in these
patients.20,21 Our data confirm that the concentrations
of CK and CK-MB increase significantly and tran-
siently on day 1 but stay within normal limits (95%
confidence interval of 20.7-30.6 for CK-MB in the con-
trol group vs 31.7-44.4 for the reinfusion group, P
=.002). The troponin levels remained similar in the 2
groups throughout the postoperative course.
The present study recruited a heterogenous group of
patients undergoing CABG and valvular and redo oper-
ations because we expected to include higher risk
patients. Although this led to some difference in base-
line characteristics of patients between the 2 groups,
multivariate analyses suggested that patients who
would probably benefit the most from reinfusion of
mediastinal shed blood are men with low body surface
areas, low preoperative hemoglobin levels, and
increased blood loss after their operations. Page and
colleagues22 have found that the homologous blood
requirement was significantly reduced with autotrans-
fusion of mediastinal shed blood in patients whose
blood loss exceeded 500 mL after their operations.
Unfortunately, this subgroup of patients cannot be eas-
ily identified preoperatively. In our control group, 47
(47%) patients had postoperative blood loss greater
than 500 mL. Thus 1 in 2 patients could probably ben-
efit from reinfusion of mediastinal shed blood.
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Table VI.  Univariate analysis of the determinants of transfusion requirement for all patients
Characteristics Odds ratio (95% CI) P value
Age (y) 1.06 (1.02-1.10) .0002
Sex (male) 6.36 (2.56-15.82) .00007
Preoperative red cell mass (g · L–1 · m–2) 0.97 (0.96-0.98) <.00001
Antifibrinolytic agent 0.302 (0.15-0.63) .001
Mediastinal drainage (mL) 1.001 (1.0005-1.002) .0002
Reinfusion of mediastinal blood 0.45 (0.25-0.82) .009
CI, Confidence interval.
Table VII.  Multivariate analysis of the determinants of transfusion requirement for all patients
Characteristics Odds ratio (95% CI) P value
Age (y) 1.03 (1.007-1.06) .2
Sex (male) 3.73 (2.02-6.90) .03
Preoperative red cell mass (g · L–1 · m–2) 0.97 (0.965-0.98) .00006
Antifibrinolytic agent 0.78 (0.47-1.29) .6
Mediastinal drainage (mL) 1.002 (1.0018-1.003) .00002
Reinfusion of mediastinal blood 0.24 (0.15-0.38) .002
CI, Confidence interval.
We understand that the use of homologous blood prod-
ucts in 73% and 55% of control and reinfused patients
after various cardiac surgical operations remains a high
rate of use of blood transfusion. In a recent multicenter
controlled clinical trial that enrolled 838 critically ill
patients and compared a restrictive with a liberal strategy
of red cell transfusion in intensive care units, Hébert and
colleagues23 have shown that the restrictive strategy, with
a threshold for hemoglobin concentration of 7 g/dL, was
at least as effective and possibly superior in terms of the
30-day mortality compared with a liberal strategy of
transfusion. Thus, the recommendation of Hébert and
colleagues, stating that critically ill patients receive red
cell transfusions only when their hemoglobin concentra-
tions fall below 7 g/dL and that hemoglobin concentra-
tion should be maintained between 7 and 9 g/dL, could
further reduce the need for homologous blood transfusion
in patients after cardiac operations.
In summary, we confirm that the autotransfusion of
mediastinal shed blood after cardiac operations is safe
and reduces the number of patients exposed to homolo-
gous blood products. Preoperative determinants of
patients who would most benefit from autotransfusion of
mediastinal shed blood includes male sex, anemic status,
and lower body surface area. The exact cause of increased
shed blood in reinfused patients despite normal coagula-
tion parameters remains unclear but could be simply
related to a greater mechanical efficacy of the autotrans-
fusion closed drainage system compared with the effect
of soft sump drains used in the control group of patients.
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